Telisotuzumab vedotin 中文名称

Author: rfjb

August undefined, 2024

WebJun 16, 2024 · Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of Teliso-V or Docetax at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab … WebApr 13, 2024 · D. Ross Camidge, MD, PhD. Single-agent telisotuzumab vedotin (teliso-v; ABBV-399) induced an encouraging objective response rate (ORR) with a tolerable safety profile in patients with previously ...

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) …

WebAug 11, 2024 · Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been … Web2024年01月11日讯 /生物谷BIOON/ --艾伯维（AbbVie）近日宣布，美国食品和药物管理局（FDA）已授予telisotuzumab vedotin（Teliso-V）突破性疗法认定（BTD ... jeff longo

EMEA-002361-PIP01-18 European Medicines Agency

Web艾伯维（AbbVie）近日宣布，美国食品和药物管理局（FDA）已授予telisotuzumab vedotin（Teliso-V）突破性疗法认定（BTD），用于治疗：接受含铂方案治疗期间或之后疾病进展、c-Met高水平过度表达、晚期/转移性表皮生长因子受体（EGFR）野生 … WebMar 1, 2024 · Telisotuzumab vedotin is an anti-MET ADC targeting MET-overexpressing solid tumors. It has an anti-MET antibody linked to MMAE with a DAR of 3.1. Telisotuzumab vedotin delivers MMAE to the tumor cells via the MET receptor directly. It has shown activity in both c-MET-amplified and MET-overexpressing tumor cells in mouse xenograft … WebJun 14, 2024 · Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of Teliso-V or Docetax at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 698 adult participants with c-Met … jeff lupinacci

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With ...

A Study to Assess Disease Activity and Adverse Events of …

WebTelisotuzumab [WHO-DD] Source: Common Name English HUMANIZED IGG1 ANTI-C-MET ANTIBODY: Source: Common Name ... TELISOTUZUMAB VEDOTIN. CONJUGATE -> PARENT Amount: Related Record Type Details; R15ZW356HN. TELISOTUZUMAB. ACTIVE MOIETY Name Property Type Amount Referenced Substance WebJul 1, 2024 · Abstract. Background: Teliso-V is an anti-c-Met antibody conjugated with a tubulin inhibitor MMAE. The aim of this phase 2 trial (NCT03539536) is to explore safety and efficacy of teliso-V in cohorts (based on histopathology and EGFR mutation) and … jeff luong at\\u0026tWebJan 5, 2024 · The FDA has granted a breakthrough therapy designation to telisotuzumab vedotin (ABBV-399; teliso-V) for use in patients with advanced or metastatic EGFR wild-type, nonsquamous non–small cell ... jeff lozama

"WebNov 1, 2024 · Purpose: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks … " - Telisotuzumab vedotin 中文名称

Telisotuzumab vedotin 中文名称

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both

WebNov 1, 2024 · Telisotuzumab vedotin (teliso-V) in combination with erlotinib (Tarceva) induced promising outcomes in patients with advanced, EGFR -mutated, c-MET-positive non–small cell lung cancer (NSCLC ... WebAug 3, 2024 · 这些研究数据初步揭示了 Telisotuzumab Vedotin 对于 c-Met 过表达 NSCLC 患者具有一定的疗效。 c-Met 为一种受体酪氨酸激酶，可通过与其配体肝细胞生长因子结合后，激活多种不同的细胞信号通路，包括有关增殖、运动、迁移及侵袭的细胞信号通路。

Did you know?

WebJan 5, 2024 · The FDA has granted a breakthrough therapy designation to telisotuzumab vedotin (teliso-V) for patients with advanced or metastatic EGFR wild-type nonsquamous non–small cell lung cancer with high levels of c-Met overexpression who have progressed on a platinum-based therapy, according to a press release from AbbVie. 1. The … WebApr 16, 2024 · A promising objective response rate (ORR) and a tolerable safety profile were observed with telisotuzumab vedotin (teliso-v; ABBV-399) monotherapy to treat patients with previously treated c-Met–positive advanced non–small cell lung cancer (NSCLC), according to data from a phase 2 trial (NCT03539536) at the American Association for …

WebTisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is … WebMay 29, 2024 · Study Description. Go to. Brief Summary: This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population (s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line …

WebOct 4, 2024 · Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalation, three to six patients with advanced solid tumors were enrolled in eight cohorts (0.15 to … WebSep 13, 2024 · 新着一覧へニュース. 2024/09/13. 治療歴のあるc-Met陽性非扁平上皮EGFR野生型NSCLCにTelisotuzumab Vedotin単剤は有望な奏効率を示す【WCLC 2024】

WebNov 4, 2024 · The use of telisotuzumab vedotin (ABBV-399) plus erlotinib (Tarceva) for patients with c-MET protein expressing non–small cell lung cancer (NSCLC) showed promising antitumor activity, according to results published in the Journal of Clinical Oncology. 1. Findings from a phase 1/1b study multicenter, open-label study …

Web药物名称或方案：Telisotuzumab Vedotin（抗c-MET单克隆抗体）适合对象：既往接受过系统性治疗（系统治疗可以是化疗、免疫治疗或针对驱动基因的靶向治疗）后仍出现疾病进展，但未接受过c-MET靶向抗体治疗的c-Met+局部晚期或转移性非小细胞肺癌患者 lagu sekolah minggu laskar kristusWebMay 29, 2024 · This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). lagu sekolah minggu jalan serta yesusWebJun 2, 2024 · Abstract. PDF. 9016. Background: Teliso-V is an antibody-drug conjugate composed of a c-Met antibody (ABT-700) and a microtubule inhibitor (monomethyl auristatin E). The phase 2 M14-239 trial (LUMINOSITY, NCT03539536) aims to identify the c-Met … jeff lusich judgeWebSep 2, 2024 · The ADC known as telisotuzumab vedotin is currently undergoing clinical evaluation in MET-expressing NSCLC . This ADC consists of the ABT-700 MET antibody conjugated to monomethyl auristatin E (MMAE) via a cathepsin-cleavable linker ( 21 ). lagu sekolah minggu mari kita bersukariaWebJul 1, 2024 · Abstract. Background: Teliso-V is an anti-c-Met antibody conjugated with a tubulin inhibitor MMAE. The aim of this phase 2 trial (NCT03539536) is to explore safety and efficacy of teliso-V in cohorts (based on histopathology and EGFR mutation) and subgroups (based on c-Met expression) of patients with c-Met+ advanced NSCLC (stage 1), … jeff lutz biographyWebDec 4, 2024 · Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated. Methods: In a phase 1b study (NCT02099058), adult patients (≥18 … jeff lupica podiatristWebDec 4, 2024 · Telisotuzumab vedotin (Teliso-V; ABBV-399) is an anti–c-Met ADC composed of the monoclonal antibody ABT-700 and the microtubule inhibitor monomethyl auristatin E (MMAE). Receptor-mediated internalization of Teliso-V by c-Met–expressing tumor cells leads to the intracellular release of MMAE, inhibition of cell division, and … lagu sekolah minggu natal